#Breaking : Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma , or #DLBCL . Learn more: gene.com/media/press-re…

#Breaking : NEJM publishes Phase III data demonstrating our medicine significantly reduced allergic reactions across multiple foods in people with #FoodAllergies . Learn more: gene.com/media/press-re…

#Breaking : The U.S. FDA approved our treatment as the first and only medicine for children and adults with one or more #FoodAllergies . Learn more: gene.com/media/press-re…

#Breaking : New long-term data from our global Phase III studies for the treatment of retinal vein occlusion will be presented at this year’s #Angiogenesis2024 medical meeting. Learn more about the data results here: gene.com/media/press-re… #EyeHealth #Retina

#Breaking : We’re presenting new pivotal data at #SABCS23 demonstrating the significant benefit of our investigational combination therapy on disease progression in certain types of advanced HR+/HER2- #breastcancer . Learn more: gene.com/media/press-re…

#Breaking : Long-term data at #SABCS23 shows significant overall survival benefit in people with HER2-positive early-stage #breastcancer . Read more about the results here: gene.com/media/press-re…

ICYMI: We announced Phase III data that showed our investigational combination therapy for certain types of advanced #breastcancer met its primary endpoint of progression-free survival. Read more: bit.ly/3tc5hfq

#Breaking : Primary endpoint was met in a Genentech Phase III trial for people with certain types of advanced #breastcancer . gene.com/media/press-re…

Wow! Heartfelt congratulations to our Informatics colleagues for landing the number one spot among large organizations on the Computerworld Best Places to Work in IT list! Learn more: bit.ly/3SZXrA5 #BestPlacesIT

#Breaking : We're announcing our collaboration with NVIDIA to accelerate the discovery and development of new medicines by combining our AI and research expertise with NVIDIA's computing and AI capabilities. Learn more: gene.com/media/press-re…

Thank you Discovery Education for your partnership through Futurelab+ to help expand access to inclusive biotech education. Learn more: bit.ly/3PvqERW

We've expanded our support for UC Merced with a $1M grant to enable community health workers to bridge cultural gaps between patients & care providers, co-lead research efforts, and serve as policy advocates to advance health outcomes in California and beyond. Learn more here:…

#Breaking : Our treatment for macular edema following retinal vein occlusion (RVO) has been approved by the U.S. FDA. Read more here: gene.com/media/press-re… Genentech Ophthalmology

In 2013, Ira Mellman & Dan Chen helped transform how we understood the immune response to cancer with the cancer-immunity cycle. While the framework remains unchanged, scientists have since made great progress informing potential new immunotherapies: bit.ly/3QFST0t

ICYMI: At #ESMO2023 , we announced positive Phase III data of our targeted therapy in ALK-positive early-stage NSCLC. Learn more: bit.ly/3tIXAgV